RELY News & Events

Remitly Global (RELY) will replace Apellis Pharmaceuticals (APLS). S&P 500 constituent Biogen (BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.

Year over year growth in net income for 2026 and Adjusted EBITDA to be in the range of $370 million to $385 million.